Information  X 
Enter a valid email address

Cellular Goods PLC (CBX)

  Print   

Friday 26 February, 2021

Cellular Goods PLC

First Day of Dealings

RNS Number : 4260Q
Cellular Goods PLC
26 February 2021
 

Press Release

26 February 2021

NOT FOR PUBLICATION OR RELEASE IN OR INTO THE UNITED STATES OR AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH AFRICA, OR ANY PROVINCE OR TERRITORY THEREOF OR TO OR FOR THE ACCOUNT OF ANY NATIONAL, RESIDENT OR CITIZEN OF THE UNITED STATES OR ANY PERSON RESIDENT IN AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH AFRICA.

 

 Cellular Goods PLC

("Cellular Goods" or "the Company")

 

First day of dealings

Admission to the Official List

 

Cellular Goods, a UK-based provider of premium consumer products based on biosynthetic cannabinoids, is pleased to announce that share dealings in its ordinary shares of £0.001 each will commence on the main market of the London Stock Exchange from 8am today under the ticker symbol CBX.

The Company has been admitted to the standard segment of the Official List following a significantly oversubscribed initial public offering that raised £13 million before expenses for the Company.

More than 6,000 valid applications for shares were received in respect of the IPO.

Cellular Goods is the first provider of premium consumer products based on biosynthetic cannabinoids to join the London stock market.

A total of 260,000,000 ordinary shares (representing 51.5% of the Company's issued share capital on Admission) have been issued at 5 pence each to institutional and retail investors, valuing Cellular Goods at a market capitalisation in excess of £25 million.

On admission, the Company will have 504,750,000 ordinary shares in issue.

Tennyson Securities and Novum Securities acted as joint bookrunners and brokers to the Company. PrimaryBid acted as retail adviser.

The purpose of the flotation is to raise the public profile and provide new funds for the Company's expansion and long-term growth.

Commenting on Cellular Goods' flotation, Alexis Abraham, Chief Executive Officer, said, " Cellular Goods' debut on the London Stock Exchange is a major step in the Company's development and provides a strong foundation to execute our long-term growth strategy. We are delighted with the strong support from a wide range of institutional and retail investors to build premium consumer products based on biosynthetic cannabinoids under the Cellular Goods brand."

 

Company highlights

Cellular Goods was established in August 2018 to develop efficacy-led and research-backed cannabinoid products. The initial focus is on two product verticals: premium skincare and topical athletic recovery products to be launched from this autumn. These will be made available through partnerships with leading online and physical retailers and direct to consumers through the Company's website.

The Company has partnered with four leading biosynthetic cannabinoid producers in the United States who have experience and expertise in the manufacture of these compounds through a fermentation-based process to secure a consistent supply of legally-compliant raw materials.

The production of biosynthetic cannabinoids does not involve the cultivation or processing of the cannabis sativa plant.

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

 

Cellular Goods 

 

Alexis Abraham

Chief Executive

 

Neil Thapar

Investor Relations

+44 207 031 6871

 

 

 

+44 787 645 5323

Tennyson Securities

 

Corporate Broker

Peter Krens

 

+44 207 186 9030

Novum Securities

 

Corporate Broker

Colin Rowbury

Jon Belliss

 

 

 

+44 207 399 9427  

 

PrimaryBid

 

Retail Adviser

James Deal

 

Mike Coombes 

 

+44 203 026 4750

 

 

 

Tancredi Intelligent Communication

Media Relations

 

Helen Humphrey

Edward Daly

Salamander Davoudi

[email protected]

 

+44 744 922 6720

+44 795 429 2488

+44 795 754 9906

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
LISEANASAALFEFA

a d v e r t i s e m e n t